Cost-effectiveness of ocriplasmin for the treatment of vitreomacular traction and macular hole

References

• Johnson MW, Van Newkirk MR, Meyer KA. Perifoveal vitreous detachment is the primary pathogenic event in idiopathic macular hole formation. Arch Ophthalmol. 2001; 119(2): 215–22. [PubMed Abstract].
   Google Scholar
• Jackson TL, Nicod E, Simpson A, Angelis A, Grimaccia F, Kanavos P. Symptomatic vitreomacular adhesion. Retina. 2013; 33(8): 1503–11. [PubMed Abstract].
   Google Scholar
• Jackson TL, Donachie PH, Johnston RL, Vitreomacular Traction Study Group . Electronic medical record database study of vitrectomy and observation for vitreomacular traction. Retina 2016. [Epub ahead of print]..
   Google Scholar
• Jackson TL, Nicod E, Angelis A, Grimaccia F, Prevost AT, Simpson AR, etal. Pars plana vitrectomy for vitreomacular traction syndrome: A systematic review and meta-analysis of safety and efficacy. Retina. 2013; 33(10): 2012–7. [PubMed Abstract].
   Google Scholar
• Koerner F, Garweg J. Vitrectomy for macular pucker and vitreomacular traction syndrome. Doc Ophthalmol. 1999; 97(3–4): 449–58. [PubMed Abstract].
   Google Scholar
• Jackson TL, Donachie PH, Sparrow JM, Johnston RL. United Kingdom National Ophthalmology Database study of vitreoretinal surgery: Report 2, macular hole. Ophthalmology. 2013; 120(3): 629–34. [PubMed Abstract].
   Google Scholar
• Stalmans P, Benz MS, Gandorfer A, Kampik A, Girach A, Pakola S, etal. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med. 2012; 367(7): 606–15. [PubMed Abstract].
   Google Scholar
• Haller JA, Stalmans P, Benz MS, Gandorfer A, Pakola SJ, Girach A, etal. Efficacy of intravitreal ocriplasmin for treatment of vitreomacular adhesion: Subgroup analyses from two randomized trials. Ophthalmology. 2015; 122(1): 117–22. [PubMed Abstract].
   Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013; London, England: NICE.
   Google Scholar
• National Institute for Health and Care Excellence. Ocriplasmin for treating vitreomacular traction. Technology appraisal guidance 297. 2013; London, England: NICE.
   Google Scholar
• Foos RY, Wheeler NC. Vitreoretinal juncture. Synchysis senilis and posterior vitreous detachment. Ophthalmology. 1982; 89(12): 1502–12. [PubMed Abstract].
   Google Scholar
• Laitinen A, Koskinen S, Harkanen T, Reunanen A, Laatikainen L, Aromaa A. A nationwide population-based survey on visual acuity, near vision, and self-reported visual function in the adult population in Finland. Ophthalmology. 2005; 112(12): 2227–37. [PubMed Abstract].
   Google Scholar
• Hikichi T, Yoshida A, Trempe CL. Course of vitreomacular traction syndrome. Am J Ophthalmol. 1995; 119: 55–61. [PubMed Abstract].
   Google Scholar
• Czoski-Murray C, Carlton J, Brazier J, Young T, Papo NL, Kang HK. Valuing condition-specific health states using simulation contact lenses. Value Health. 2009; 12(5): 793–9. [PubMed Abstract].
   Google Scholar
• Edwards SJ, Barton S, Trevor N, Lois N, Nherera L, Hamilton V. Ranibizumab for the treatment of macular oedema caused by retinal vein occlusion (RVO): A single technology appraisal. 2011; London, England: BMJ-TAG.
   Google Scholar
• National Institute for Health and Care Excellence. Fluocinolone acetonide intravitreal implant for the treatment of chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271). 2013; London, England: NICE. Technology Appraisal Guidance 301.
   Google Scholar
• D'Souza MJ, Chaudhary V, Devenyi R, Kertes PJ, Lam WC. Re-operation of idiopathic full-thickness macular holes after initial surgery with internal limiting membrane peel. Br J Ophthalmol. 2011; 95(11): 1564–7. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Haute Autorité de Santé. JETREA 0.5 mg/0.2 ml concentrate for solution for injection. 2013; Saint-Denis, France: HAS. Transparency Committee Opinion.
   Google Scholar
• Meads C, Hyde C. What is the cost of blindness?. Br J Ophthalmol. 2003; 87(10): 1201–14. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, etal. State-transition modeling: A report of the ISPOR-SMDM modeling good research practices task force-3. Value Health. 2012; 15: 812–20. [PubMed Abstract].
   Google Scholar
• National Institute for Health and Care Excellence. Lucentis (ranibizumab) for the treatment of visual impairment due to diabetic macular oedema (rapid review of technology appraisal guidance 237). Technology Appraisal Guidance 274. 2013; London, England: NICE.
   Google Scholar
• National Institute for Health and Care Excellence. Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion. Technology Appraisal Guidance 229. 2011; London, England: NICE.
   Google Scholar
• Mitchell P, Annemans L, Gallagher M, Hasan R, Thomas S, Gairy K, etal. Cost-effectiveness of ranibizumab in treatment of diabetic macular oedema (DME) causing visual impairment: Evidence from the RESTORE trial. Br J Ophthalmol. 2012; 96(5): 688–93. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Institute for Quality and Efficiency in Health Care. Ocriplasmin – benefit assessment according to § 35a Social Code Book V (dossier assessment) [in German]. 2013; Cologne, Germany: IQWiG. Commission No. A13-20.
   Google Scholar
• Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, etal. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: A report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013; 16: 231–50. [PubMed Abstract].
   Google Scholar
• Chang JS, Smiddy WE. Cost evaluation of surgical and pharmaceutical options in treatment for vitreomacular adhesions and macular holes. Ophthalmology. 2014; 121(9): 1720–6. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Centre for Reviews and Dissemination at the University of York. Systematic reviews: CRD's guidance for undertaking reviews in health care. 2009; York, England: CRD.
   Google Scholar
• Choosing interventions that are cost-effective (WHO-CHOICE).World Health Organization. Available from: http://www.who.int/choice/costs/en/ [cited 9 December 2013]..
   Google Scholar